NYSE: ALURAllurion Technologies Inc Stock
$2.34+0.09 (+4%)
Updated Apr 17, 2025
ALUR Price
$2.34
Fair Value Price
N/A
Market Cap
$13.95M
52 Week Low
$2.15
52 Week High
$88.75
P/E
-0.2x
P/B
-0.18x
P/S
0.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.11M
Earnings
-$26.15M
Gross Margin
67%
Operating Margin
-72.15%
Profit Margin
-81.4%
Debt to Equity
-1.42
Operating Cash Flow
-$42M
Beta
0.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALUR Overview
Compute Health Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets opportunities at the intersection of computation and healthcare. The company was founded in 2020 and is headquartered in Wilmington, DE.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALUR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ALUR
Ranked#102 of 102
Ranked#102 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important ALUR news, forecast changes, insider trades & much more!
ALUR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALUR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALUR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ALUR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ALUR due diligence checks available for Premium users.
Valuation
ALUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
41.14x
Market
27.98x
ALUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.18x
Industry
3.8x
ALUR's financial health
Profit margin
Revenue
$5.6M
Net Income
-$20.6M
Profit Margin
-367.9%
ALUR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALUR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.8M
Liabilities
$110.8M
Debt to equity
-1.42
ALUR's short-term assets ($27.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALUR's long-term liabilities ($91.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALUR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.3M
Investing
$0.0
Financing
-$53.0k
ALUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALUR vs Medical Device Stocks
Allurion Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.